Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory & Other Diseases evaluates the competitive landscape of bispecific therapeutic antibodies for treatment of cancer, anti-inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, neurologic, ophthalmic and pulmonary diseases as of June 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Tremendous progress in bispecific antibody technologies during the last decade has lead to an explosion of the number of bispecific antibodies in clinical development. This report describes 47 clinical and further 25 pre-IND stage bispecific antibodies in addition to numerous preclinical R&D programs. The two specificities provide flexibility in the use as:

T-Cell or NK cell redirecting bispecific cancer antibodies
Bispecific immuno-oncology antibodies
Bispecific tumor antigens targeted cancer antibodies
Bispecific antibodies for inflammatory & autoimmune diseases
Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases

The report includes a compilation of currently active projects in development of bispecific therapeutic antibodies including cocktails of antibodies as well as oligo- and polyclonal antibodies. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents:

听

1.听听Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

T-Cell Redirecting Bispecific Cancer Antibodies
NK Cell Redirecting Bispecific Cancer Antibodies
Bispecific Immuno-Oncology Antibodies
Bispecific Tumor Antigens Targeted Cancer Antibodies
Bispecific Antibodies for Inflammatory & Autoimmune Diseases
Bispecific Antibodies Outside Oncology & Inflammation
Antibody Cocktails & Oligo- and Polyclonal Antibodies

2.听听Corporate Bispecific Antibody Pipelines

Companies Mentioned:

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

麻豆原创